title: Risk of kava hepatotoxicity and the FDA consumer advisory.
authors.affiliation: Department of Internal Medicine II, Klinikum Hanau, Teaching Hospital of the Johann Wolfgang Goethe-University of Frankfurt/Main, Leimenstrasse 20, D-63450 Hanau, Germany. rolf.teschke@gmx.de
authors.forename: Rolf
authors.initials: R
authors.lastname: Teschke
authors.forename: Johannes
authors.initials: J
authors.lastname: Schulze
mesh_terms: D056486:Chemical and Drug Induced Liver Injury; D003132:Commerce; D003254:Consumer Advocacy; D019587:Dietary Supplements / Q000009:adverse effects / Q000592:standards; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D020901:Kava / Q000009:adverse effects* / Q000145:classification; D008099:Liver / Q000187:drug effects*; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects* / Q000145:classification; D011640:Public Policy; D014481:United States; D014486:United States Food and Drug Administration; D014944:World Health Organization
chemical_list: D010936:Plant Extracts